RT @KDAO2011: $26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered

Tweet Author

KDAO2011

Tweet Content

$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v

Links

Health System Improvement in Inpatient ANA and Serologic Test Utilization - ACR… https://acrabstracts.org/abstract/health-system-improvement-in-inpatient-ana-an…

RT @RichardPAConway: Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, sw

Tweet Author

RichardPAConway

Tweet Content

Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, swollen and tender joint counts week 48. Strange, the lowest dose (3mg bd) seems best. @RheumNow #ACR22 Abstr#1117 #ACRbest https://t.co/o4902tvZs8 https://t.co/t8oeMRGUS7

Links

Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh… https://acrabstracts.org/abstract/efficacy-and-safety-of-deucravacitinib-an-ora…

RT @ericdeinmd: @RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at

Tweet Media

Tweet Author

ericdeinmd

Tweet Content

@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22 @jhrheumatology @JHRheumFellows https://t.co/aSRHiJoIkE

RT @RichardPAConway: Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR

Tweet Author

RichardPAConway

Tweet Content

Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H

Links

Multimorbidity in Psoriasis as a Risk Factor for Psoriatic Arthritis: A Populat… https://acrabstracts.org/abstract/multimorbidity-in-psoriasis-as-a-risk-factor-…

RT @uptoTate: 2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 y

Tweet Author

uptoTate

Tweet Content

2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 years, but after trial termination, protective effects dissipated and were no longer significant. #ACR22 @RheumNow https://t.co/sLwoxeCR3y https://t.co/47wpWXF1W7

Links

Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmun… http://ow.ly/9K6U50Lz3b7

RT @AurelieRheumo: HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-ris

Tweet Author

AurelieRheumo

Tweet Content

HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-risk Interim analysis 140+ pts RA development HCQ 34% vs. PBO 36% Trial interrupted as met futility criteria. https://t.co/n31OmsjLhM Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to

Links

Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthri… http://bit.ly/3TyjiLI

RT @ericdeinmd: 2022 ACR G/L for Integrative RA Intervent #ACR22 1 strong rec: consistent exercisee 27 conditional recs:

Tweet Author

ericdeinmd

Tweet Content

2022 ACR G/L for Integrative RA Intervent #ACR22 1 strong rec: consistent exercisee 27 conditional recs: Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct Conditional against electrotherapy, chiropractor No rec for diet supplem BMI, 🚬: no RA spec recomm @RheumNow https://t.co/cVFr6beQuJ

RT @RichardPAConway: Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for d

Tweet Author

RichardPAConway

Tweet Content

Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for dialysis 75.6% vs 16.7%, p=0.023. No effect on overall survival. 5-year mortality 70%, 1 year mortality 58%. @RheumNow #ACR22 Abstr#1530 https://t.co/cdYhEtqcHT https://t.co/lDWJto1cF0

Links

Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortali… https://acrabstracts.org/abstract/scleroderma-renal-crisis-time-to-initiation-o…

RT @RichardPAConway: Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in

Tweet Author

RichardPAConway

Tweet Content

Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in outcomes than late initiators (at least in MDA) in CorEvitas. @RheumNow #ACR22 Abstr#1493 https://t.co/oadxbG8TKS https://t.co/245xVTcKx1

Links

Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs… https://acrabstracts.org/abstract/impact-of-delay-of-treatment-with-disease-mod…

RT @RichardPAConway: Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experi

Tweet Author

RichardPAConway

Tweet Content

Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experienced equiv to normal drop off at 1 year on a biologic. Lower retention 83% in originator-naive switchers = likely nocebo effect @RheumNow #ACR22 Abstr#1112 https://t.co/oa1SawWWs4 https://t.co/iU3doB9jV4

Links

Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patie… https://acrabstracts.org/abstract/biosimilar-to-biosimilar-switching-in-routine…

Topics

RT @KDAO2011: $26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered

RT @RichardPAConway: Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, sw

RT @ericdeinmd: @RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at

RT @RichardPAConway: Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR

RT @uptoTate: 2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 y

RT @AurelieRheumo: HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-ris

RT @ericdeinmd: 2022 ACR G/L for Integrative RA Intervent #ACR22 1 strong rec: consistent exercisee 27 conditional recs:

RT @RichardPAConway: Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for d

RT @RichardPAConway: Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in

RT @RichardPAConway: Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experi

Do you get our email newsletter?

RT @KDAO2011: $26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered

RT @RichardPAConway: Pike et al. Deucravactinib (TYK2i) in SLE. + on SRI(4) week 32. + SRI(4),BICLA, LLDAS, CLASI-50, sw

RT @ericdeinmd: @RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at

RT @RichardPAConway: Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, &gt;=2 comorbidities HR

RT @uptoTate: 2000 IU/day vitamin D led to significantly reduced incidence of autoimmune diseases in Abs 1200 over 5.3 y

RT @AurelieRheumo: HCQ does not prevent RA in CCP+ pts w/out clinical arthritis! Stop RA: RCT HCQ vs. PBO in pts at-ris

RT @ericdeinmd: 2022 ACR G/L for Integrative RA Intervent #ACR22 1 strong rec: consistent exercisee 27 conditional recs:

RT @RichardPAConway: Patel @draditipatel et al. Delay in starting ACE-I in Scleroderma Renal Crisis increased need for d

RT @RichardPAConway: Mease et al. PsA - Early DMARD initiators (=&lt;1 year following diagnosis) greater improvement in

RT @RichardPAConway: Nabi. Biosimilar to biosimilar IFX switch in DANBIO. High retention rate - 92% in originator-experi

RT @RichardPAConway: Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR

RT @RichardPAConway: Mease et al. PsA - Early DMARD initiators (=<1 year following diagnosis) greater improvement in